Abbott India Limited vs GlaxoSmithKline Pharmaceuticals Limited
An objective side-by-side of ABBOTINDIA and GLAXO, both in Pharmaceuticals - Multinational: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-11-05 close
Latest results: ABBOTINDIA Jun 2026 · GLAXO Sep 2026
At a glance
- Abbott India Limited is the larger company by market value, about 1.3 times the size of GlaxoSmithKline Pharmaceuticals Limited.
- On trailing earnings, Abbott India Limited trades at the lower P/E (35.0 against 36.9).
- GlaxoSmithKline Pharmaceuticals Limited earns the higher return on equity (61.0% against 33.8%).
- Over three years GlaxoSmithKline Pharmaceuticals Limited has grown profits faster (18% a year against 18%).
- Over the past year the share prices returned -10.1% (ABBOTINDIA) and -4.6% (GLAXO).
| Metric | Abbott India ABBOTINDIA |
GlaxoSmithKline Pharmaceuticals GLAXO |
|---|---|---|
| Size and price | ||
| Market cap | ₹56,534 Cr | ₹42,355 Cr |
| Share price | ₹26,605.00 | ₹2,500.20 |
| Valuation | ||
| P/E | 35.00 | 36.94 |
| P/B | 11.84 | 22.52 |
| EV/EBITDA | 28.80 | 29.86 |
| PEG | 1.94 | 2.05 |
| Dividend yield | 2.0% | 2.3% |
| Profitability | ||
| ROE | 33.8% | 61.0% |
| ROCE | 45.0% | 61.0% |
| Operating margin | 28.1% | 34.1% |
| Sales (TTM) | ₹7,005 Cr | ₹4,158 Cr |
| Net profit (TTM) | ₹1,615 Cr | ₹1,147 Cr |
| Growth | ||
| Latest quarter sales YoY | +4.4% | +20.8% |
| Latest quarter profit YoY | +17.2% | +30.7% |
| Sales CAGR 3Y | +9.0% | +6.0% |
| Profit CAGR 3Y | +18.0% | +18.0% |
| Sales CAGR 5Y | +10.0% | +5.0% |
| Profit CAGR 5Y | +18.0% | +15.0% |
| Financial strength | ||
| Debt/Equity | 0.04 | 0.02 |
| Interest cover | 72.60 | 420.19 |
| Ownership | ||
| Promoter holding | 75.0% | 75.0% |
| Promoter change (4 qtrs) | — | +0.00 pp |
| Price performance | ||
| Return 1M | +1.88% | -9.25% |
| Return 3M | -4.25% | -2.70% |
| Return 1Y | -10.12% | -4.63% |
| Return YTD | -8.34% | +1.08% |
| Technical condition | ||
| Technical score | 57 | 24 |
| RS rating (1-99) | 57.00 | 63.00 |
| % vs 200-DMA | -0.08% | -0.63% |
| RSI (14) | 55.34 | 41.56 |
| % from 52-week high | -13.21% | -19.88% |
